Dr. Lejla Vajzovic, MD
Claim this profileDuke Eye Center
Studies Retinitis Pigmentosa
Studies Retinal Disease
7 reported clinical trials
10 drugs studied
Affiliated Hospitals
Clinical Trials Lejla Vajzovic, MD is currently running
OCT Imaging Systems
for Retinal Disease in Children
Handheld optical coherence tomography (OCT) has become an important imaging modality to evaluate the pediatric retina. The objective of this pilot study is to compare a new contact OCT system (Theia Imaging) with an investigational noncontact OCT system (Duke Biomedical Engineering) to assess their ability to image the pediatric retina. The investigators hypothesize that the contact OCT system is superior in imaging larger areas of the retina (larger field-of-view), while it has similar resolution to image the retina substructures (non-inferior image quality).
Recruiting1 award N/A8 criteria
High-Speed Eye Scanning Technology
for Retinopathy of Prematurity
Retinopathy of prematurity (ROP) is a disorder of development of the neural retina and its vasculature that can impact vision in vulnerable preterm neonates for a lifetime. This study tests high-speed optical coherence tomography (OCT) technology compared to conventional color photographs at the bedside of very preterm infants in the intensive care nursery, to characterize previously unseen abnormalities that can predict a need for referral for ROP treatment, or poor visual or neurological development later in life, up to pre-school age. Our long-term goal is to help improve preterm infant health and vision via objective bedside imaging and analysis that characterizes early critical indicators of ROP, and poor visual function and neurological development, which will rapidly translate to better early intervention and improved future care.
Recruiting1 award N/A
More about Lejla Vajzovic, MD
Clinical Trial Related1 year of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Lejla Vajzovic, MD has experience with
- AAV5-RPGR
- SPECTRALIS
- SPECTRALIS With Flex Module
- Dextenza 0.4Mg Ophthalmic Insert
- Pred Forte
- Swept Source OCT
Breakdown of trials Lejla Vajzovic, MD has run
Retinitis Pigmentosa
Retinal Disease
Retinopathy of Prematurity
Idiopathic Retinal Telangiectasia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Lejla Vajzovic, MD specialize in?
Lejla Vajzovic, MD focuses on Retinitis Pigmentosa and Retinal Disease. In particular, much of their work with Retinitis Pigmentosa has involved PR positive patients, or patients who are undergoing treatment.
Is Lejla Vajzovic, MD currently recruiting for clinical trials?
Yes, Lejla Vajzovic, MD is currently recruiting for 2 clinical trials in Durham North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Lejla Vajzovic, MD has studied deeply?
Yes, Lejla Vajzovic, MD has studied treatments such as AAV5-RPGR, SPECTRALIS, SPECTRALIS with Flex Module.
What is the best way to schedule an appointment with Lejla Vajzovic, MD?
Apply for one of the trials that Lejla Vajzovic, MD is conducting.
What is the office address of Lejla Vajzovic, MD?
The office of Lejla Vajzovic, MD is located at: Duke Eye Center, Durham, North Carolina 27705 United States. This is the address for their practice at the Duke Eye Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.